Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $469.55, marking a +1.15% move from the previous day. The stock's change was more than the S&P 500's daily gain of 0.32%. Meanwhile, the Dow gained 0.53%, and the Nasdaq, a tech-heavy index, added 0.26%. Coming into today, shares of the drugmaker had gained 5.03% in the past month. In that same time, the Medical sector lost 3.4%, while the S&P 500 gained 4.51%. Market participants will be closely following the financial results of Vertex Pharmaceuticals in its upcoming release. The company plans to announce its earnings on August 4, 2025. The company is predicted to post an EPS of $4.25, indicating a 133.13% growth compared to the equivalent quarter last year. Our most recent consensus estimate is calling for quarterly revenue of $2.89 billion, up 9.23% from the year-ago period. In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $17.81 per share and a revenue of $11.91 billion, indicating changes of +4140.48% and +8.09%, respectively, from the former year. Investors should also pay attention to any latest changes in analyst estimates for Vertex Pharmaceuticals. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As a result, we can interpret positive estimate revisions as a good sign for the business outlook. Our research shows that these estimate changes are directly correlated with near-term stock prices. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system. The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.07% higher within the past month. Vertex Pharmaceuticals currently has a Zacks Rank of #3 (Hold). In terms of valuation, Vertex Pharmaceuticals is presently being traded at a Forward P/E ratio of 26.07. This signifies a premium in comparison to the average Forward P/E of 17.83 for its industry. The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 83, which puts it in the top 34% of all 250+ industries. The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com. Should You Invest in Vertex Pharmaceuticals Incorporated (VRTX)?Before you invest in Vertex Pharmaceuticals Incorporated (VRTX), want to know the best stocks to buy for the next 30 days? Check out Zacks Investment Research for our free report on the 7 best stocks to buy.Zacks Investment Research has been committed to providing investors with tools and independent research since 1978. For more than a quarter century, the Zacks Rank stock-rating system has more than doubled the S&P 500 with an average gain of +24.08% per year. (These returns cover a period from January 1, 1988 through May 6, 2024.)Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks